Losap

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Losap

What is Losap?

Losap is a medication that belongs to a class of drugs known as angiotensin II receptor blockers (ARBs). It is primarily used in the management of cardiovascular and renal conditions. The active ingredient in this medication is losartan potassium.

Mechanism of Action

The medication works by blocking the action of a natural substance in the body called angiotensin II. Angiotensin II is a potent vasoconstrictor, meaning it causes blood vessels to narrow. By preventing this substance from binding to its receptors, the medication allows blood vessels to relax and widen. This process helps to lower blood pressure and improves blood flow throughout the body.

Primary Uses

Losap is typically prescribed for several clinical purposes related to the heart and circulatory system:

  • Management of Hypertension: It is used to treat high blood pressure, which helps reduce the workload on the heart.
  • Cardiovascular Protection: In certain patients with specific heart conditions or enlarged hearts, it may be used to reduce the long-term risk of cardiovascular events like stroke.
  • Renal Support: It is often utilized in patients with type 2 diabetes who have developed kidney disease, as it may help slow the progression of renal damage.

Therapeutic Role

Unlike some other blood pressure medications that inhibit the production of certain enzymes, this medication targets the receptor level. This specific action provides an alternative for patients who may not tolerate other types of cardiovascular therapies. It is designed for long-term management rather than immediate symptom relief, focusing on the stabilization of vascular pressure and the protection of vital organs.

What side effects are possible with Losap?

Losap: Possible Side Effects and Safety Information

Losap (Losartan) is associated with a defined safety profile derived from official regulatory documentation, which classifies adverse reactions by frequency and physiological system. This information outlines the expected safety landscape and specific restrictions for use.


Adverse Reaction Classification

Side effects are categorized based on their rate of occurrence, reflecting data from clinical trials and post-marketing surveillance. These are grouped by System-Organ Class (SOC) to provide a clear regulatory safety map.

Frequency Classification Examples of Documented Effects (SOC)
Common (≥1/100, <1/10) Dizziness, Vertigo, Upper Respiratory Infection, Back Pain (Nervous/Musculoskeletal)
Uncommon (≥1/1,000, ≤1/100) Palpitations (Cardiac), Anemia (Blood)
Rare (≥1/10,000, ≤1/1,000) Angioedema, Hypersensitivity reactions (Immune System)

Serious Adverse Reactions and Safety Constraints

The label specifies rare but clinically critical events, including Angioedema (swelling of the face, lips, or throat) and the potential for serious Renal Function Deterioration and Hyperkalemia (high potassium levels). Monitoring for these metabolic and renal effects is a noted safety requirement.

Official safety restrictions include a contraindication in the second and third trimesters of pregnancy due to the risk of fetal injury. The medication is also contraindicated in patients with severe hepatic impairment and is not recommended for pediatric patients with a significantly reduced Glomerular Filtration Rate (GFR).

Additionally, the regulatory profile notes time-related safety patterns: symptomatic hypotension may occur, particularly in volume-depleted patients and often during the initiation of treatment or following a dose increase. This information formally structures the documented risks associated with Losap.

Overdose and Emergency Response

Overdose and when to Seek Help

Official regulatory labeling documents that the most likely clinical signs of Losap (Losartan potassium) overdosage are manifestations related to its potent blood pressure lowering effect. The primary documented presentations include hypotension (excessively low blood pressure), and changes in heart rate, specifically tachycardia (fast heartbeat) or bradycardia (slow heartbeat). Overdosage can potentially lead to severe symptomatic hypotension, which requires immediate medical assistance.

Urgent medical attention must be sought for any suspected overdosage. Management is required to be symptomatic and supportive, as specified in regulatory information. Treatment for symptomatic hypotension involves placing the patient in a supine position and administering intravenous fluids. Vasopressors may be considered if hypotension persists. The official labeling states that no specific antidote is known for Losartan overdosage, and the compounds are not removable by hemodialysis.

Monitoring and Population Notes

Extended clinical monitoring is necessary following a significant overdose. Patients may require continuous observation, including monitoring of blood pressure and heart rate, for a duration of up to 24 hours or longer if symptoms of low blood pressure persist.

Regulatory documents specify a population-specific consideration: neonates whose mothers were exposed to Losartan during pregnancy must be closely observed after birth for signs of hypotension, low urine output (oliguria), and high potassium levels (hyperkalemia).

Therapeutic Uses of Losap

Losap (Losartan) is a prescription medication primarily used to address chronic conditions involving symptoms related to systemic imbalance, and may be part of long-term symptomatic support for cardiovascular and renal health. This medication is commonly used across three critical therapeutic domains: managing persistent high blood pressure (hypertension), providing support for cardiovascular risk particularly in patients with heart structure changes, and offering kidney protection in those with Type 2 Diabetes.


Key Therapeutic Focus

Losap is applied in clinical settings that involve chronic or sustained stress on the circulatory system. This medication is used for managing chronic high blood pressure across relevant age groups. It helps to address the chronic state of symptoms that create noticeable physiological strain, assisting with maintaining pressure within healthy targets and contributes to easing the overall symptom load associated with chronic systemic imbalance. It is relevant in clinical settings marked by increased discomfort or tension associated with vascular risk factors.

“The application of this medication is relevant when supportive symptom management is appropriate for chronic conditions, rather than for immediate relief.”

In patients managing both Type 2 Diabetes and high blood pressure, Losap is used for managing conditions involving episodic or fluctuating manifestations of kidney damage, as it may assist with preserving kidney function, which supports general well-being during symptomatic periods of the disease.


Quick Fact: Supportive Management for Chronic Systemic Imbalance

Focus Area Benefit Provided Clinical Context
High Blood Pressure Contributes to easing the overall symptom load associated with chronic systemic imbalance. Applied in settings where short-term symptom stabilization is important for pressure.
Cardiovascular Risk Supports general well-being during symptomatic phases by easing the burden of risk factors. Relevant when supportive symptom management is appropriate for chronic conditions.
Diabetic Nephropathy May assist with preserving kidney function and maintaining functional stability. Used in settings marked by temporary physiological imbalance in the renal system.

Regulatory References

  1. DailyMed label from the U.S. National Library of Medicine

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Losap (Losartan) — official regulatory information


Eligibility scope

Classification Population or Condition
Allowed Adults (18+), and pediatric patients aged 6 years and older.
Not Recommended Children under 6 years; breastfeeding/lactating mothers; pediatric patients with impaired kidney function ( GFR < 30 mL/min/1.73 m^2).
Contraindicated Pregnant women (especially 2nd/3rd trimesters); patients with severe hepatic impairment; patients with known hypersensitivity to Losap; diabetic patients also taking aliskiren.

Age-related eligibility rules

Losap is approved for use in adults and in children aged 6 and older for hypertension. Use is not established and not recommended for children younger than six years. Older adults (ge 65 years) are generally eligible, but may exhibit increased sensitivity.

Condition-specific eligibility rules

Use is contraindicated in cases of severe hepatic impairment. Use requires caution in patients with mild to moderate hepatic impairment, intravascular volume depletion, and those with a history of angioedema. Certain combination products are contraindicated in severe renal impairment.

Pregnancy and lactation eligibility status

Losap is formally contraindicated in pregnancy due to the risk of fetal injury, and treatment must be discontinued as soon as pregnancy is detected. Use is not recommended while breastfeeding.


Connection to the overall eligibility profile

Official regulatory documents define eligibility through absolute contraindications related to reproductive status and severe organ impairment. Further restrictions are established by age limitations, specifically for children under six, and comorbidity exclusions, such as the dual use with aliskiren in diabetic patients.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Losap (Losartan) interactions are officially documented across several domains, including metabolic, pharmacodynamic, and specific prohibitions, as defined in government regulatory labeling.

Contraindicated Combinations

Co-administration is formally prohibited for Aliskiren in patients with Type 2 Diabetes, as this combination significantly increases the risk of renal impairment, hyperkalemia, and severe hypotension. Co-administration of Sparsentan is also formally contraindicated due to the risk of severe pharmacodynamic complications.

Pharmacodynamic Interactions

Interactions that create additive physiological effects are noted. Concomitant use with Potassium-sparing diuretics (e.g., Spironolactone, Triamterene), Potassium supplements, or salt substitutes containing potassium increases the documented risk of hyperkalemia (elevated serum potassium).

Dual blockade of the Renin-Angiotensin System (RAAS) with other agents, such as ACE Inhibitors, also increases the risk of hyperkalemia and renal issues. Co-administration with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including COX-2 inhibitors, may lead to deterioration of kidney function and a reduction of Losartan's effect, particularly in elderly or volume-depleted patients.

Exposure-Modifying and Other Interactions

Fluconazole is documented to increase Losartan exposure by approximately 70% via metabolic inhibition (CYP2C9), while Phenobarbital reduces Losartan exposure. Losartan can also elevate serum Lithium concentrations, increasing the risk of toxicity. Alcohol and Grapefruit juice are noted to cause an additive blood pressure-lowering effect and reduced efficacy, respectively.

Mechanism of Action

The mechanism of Losap is defined by its selective interruption of the body's Renin-Angiotensin-Aldosterone System (RAAS). The active molecules, Losartan and its primary, more active metabolite, EXP3174, function as competitive antagonists on the Angiotensin II Type 1 ( AT1) receptor. This interaction prevents the hormone Angiotensin II from binding. The molecular action eliminates the signal that drives vascular contraction and cellular growth processes modulated by the receptor.

By blocking the AT1 receptor, Losap removes the hormonal stimulus for vasoconstriction on arterial smooth muscle, leading to widespread vasodilation and a direct decrease in the total Systemic Vascular Resistance (SVR) in the circulatory system. Simultaneously, the mechanism suppresses Angiotensin II's stimulus for Aldosterone release. This engages a pathway that promotes sodium and water excretion, thereby influencing circulating plasma volume. These dual, mechanism-driven actions collectively reduce the resistance and volume against which the heart must pump, resulting in a change in systemic circulatory dynamics.

Dosage and Administration Information

How to Use Losap: Official Administration Guidelines

Losap (Losartan) is an oral medication, the only approved route of administration, and is primarily available as a film-coated tablet. The official usage instructions dictate a standardized approach to administration for chronic conditions.


Standard Dosing and Frequency

Losap is taken once daily across all approved indications. The standard starting dose for most adult patients is 50 mg once a day, with the usual maintenance range spanning 50 mg to 100 mg daily. The maximum recommended dose for most indications is 100 mg once daily. The full effect of a dosage change is typically assessed after one to three weeks, guiding any subsequent dose adjustments.


Contextual and Population-Specific Rules

Losap tablets may be administered with or without food and should be consumed at approximately the same time each day to maintain a consistent schedule. The tablets must be swallowed whole with water. A lower starting dose of 25 mg once daily is specifically required for patients who are volume-depleted (e.g., those on high-dose diuretics) or have existing hepatic impairment (liver disease).

In the event a dose is missed, the standard procedure is to skip the missed dose and take the next one at the regularly scheduled time; a double dose must not be taken to compensate. For pediatric patients aged 6 to 16 years, the dose is calculated by weight and should not exceed a 50 mg total daily dose.

Recent Clinical Evidence

Research evidence / Overview of Studies for Losap

Evidence for Use in Managing Persistent High Blood Pressure (Hypertension)

Research exploring Losap was evaluated in numerous Randomized Controlled Trials (RCTs) which examined outcomes related to high blood pressure. These studies typically monitored short-term changes in systolic and diastolic blood pressure in adults with essential hypertension, comparing Losap to a placebo or to other established blood pressure medications. Long-term trials were also conducted to examine outcomes related to physiological strain or stress on the cardiovascular system.

Research for this indication consists of numerous large, long-term studies and systematic reviews. However, comparative evidence is not available to fully establish the long-term cardiovascular outcome patterns when compared against every other type of available blood pressure medication, as research is focused on specific alternative treatments chosen by the study designers.


Evidence for Cardiovascular Risk Reduction in Specific Patient Groups

Losap was evaluated in dedicated, large-scale Randomized Controlled Trials focusing on a specific subgroup: those with hypertension who also had evidence of Left Ventricular Hypertrophy (LVH). These trials were designed to examine whether Losap was associated with differences in the occurrence of major cardiovascular events, particularly stroke, over several years of observation. Studies reported patterns related to the effect on the frequency of stroke, as well as tracking composite endpoints.

Subgroup analyses suggested that the patterns observed related to stroke incidence were less certain or less consistent across certain patient groups. Specifically, the findings were described as less consistent for patients identified as being of Black heritage. Research also includes studies that focused on pediatric patients (children aged 6 to 17 years) with high blood pressure, examining changes in blood pressure over short-term durations.


Evidence for Kidney Protection in Type 2 Diabetes

Losap was studied for use in adults with Type 2 Diabetes and established kidney disease, or diabetic nephropathy, in large, multi-year, placebo-controlled RCTs. Studies explored functional outcomes related to systemic or functional imbalance in the kidneys. The main outcomes monitored were composite endpoints that tracked progression to serious renal conditions, such as the need for dialysis (ESRD) or a doubling of the serum creatinine level. Evidence is limited for patients with only early-stage kidney changes.

Frequently Asked Questions (FAQ)

Common questions about Losap (FAQ)

Q: Why is Losap prescribed instead of other options?

Regulatory documents state that Losap (Losartan) may be used as an alternative treatment for conditions like chronic heart failure. This is often an option when other similar types of medicine, such as ACE inhibitors, are not considered suitable or are contraindicated for a patient, particularly if they experience a persistent cough.


Q: Is Losap safe to take long-term?

Losap is indicated for the chronic, long-term management of conditions like high blood pressure and diabetic kidney disease. Because of this long-term use, official documentation indicates that regular monitoring, often through blood and urine tests, is required to check for potential long-term changes, such as issues with kidney function and potassium levels.


Q: How long does it take for Losap to start working?

According to the official product information, the initial pharmacological effect on the body typically begins within about one hour after taking a dose. The concentration of the medicine’s active substance in the blood is described in regulatory documents as reaching its highest level within approximately three to four hours.


Q: Can Losap interact with common supplements like vitamins or herbal remedies?

Official regulatory documents explicitly caution against or prohibit the use of potassium supplements and salt substitutes containing potassium, as combining them with Losap can lead to dangerously high potassium levels (hyperkalemia). Regulatory sources do not contain standardized information on the safety profile of Losap combined with general herbal supplements.


Q: Is Losap safe for people with kidney problems?

Official regulatory guidance states that, for adults, generally no dosage adjustment is needed for mild, moderate, or severe kidney impairment, unless a patient is volume-depleted. However, the medicine is not recommended for children with significantly impaired kidney function (low GFR). Monitoring of kidney function is noted in official documentation as a safety requirement.


Q: Is it normal to feel tired when first starting Losap?

Yes, regulatory documents list fatigue and tiredness as commonly reported side effects, especially in patients taking the medicine for diabetic kidney disease. Patient information notes that many initial side effects often improve or go away as your body adjusts to the medication. If side effects persist or are severe, regulatory constraints advise seeking appropriate medical guidance.


Q: Does Losap have a high risk of drug-drug interactions?

Losap has documented interactions with several other medications, including NSAIDs, diuretics, and certain blood pressure medications. Official drug interaction checkers classify some of these combinations with Major or Moderate risk warnings, indicating that a structured risk profile exists, which requires routine professional monitoring.


Q: Does Losap require a special authorization or monitoring program?

The official label requires ongoing, regular monitoring of the patient's renal function and serum potassium levels to check for potential serious adverse effects. However, the medicine is not typically associated with a formal regulatory program requiring special authorization beyond a standard prescription and monitoring.


Q: Do I need to change my diet while on Losap?

Regulatory documents advise patients to avoid using salt substitutes that contain potassium, and also recommend avoiding grapefruit or grapefruit juice. No other general dietary requirements or restrictions are specified in the official regulatory documentation.


Q: Is Losap used for anything other than its main purpose?

Losap has several FDA-approved indications, which are its official purposes. These include treating high blood pressure, reducing the risk of stroke in high-risk patients, and treating kidney problems in patients with type 2 diabetes and high blood pressure. These approved uses represent the officially defined purposes of the medication.


Q: Does Losap cause weight gain?

Official regulatory documents do not list weight gain as a direct side effect of Losap. However, edema (swelling caused by water retention) is listed as a less common side effect, which may sometimes cause a noticeable change in weight. Unexplained weight gain is not listed as a direct side effect, but is sometimes monitored as a change in health status that warrants attention.


Q: Is Losap known to affect sleep?

The official product information lists sleep disorders and somnolence (sleepiness) as less common adverse reactions that have been reported with the use of Losap.


Q: Does Losap affect birth control pills?

Official documentation indicates that Losap may interact with specific types of oral contraceptives, such as those containing drospirenone. This is because the combination may increase the risk of hyperkalemia, or dangerously high potassium levels.


Q: Is Losap a controlled substance?

No, Losap (Losartan) is classified by the government as Not a Controlled Drug under the Controlled Substances Act, meaning it is not scheduled due to its risk of abuse or dependence.


Q: Are there generic versions of Losap available?

Yes, Losap (Losartan) is an established medication, and its active ingredient, Losartan potassium, is widely available as a generic medication.


Q: Is Losap a new medicine?

No, Losap (Losartan) is a medication with an established approval history that has been available for many years. It is currently available in a generic form, which indicates it is a long-standing, established treatment.


Q: Can Losap affect mood or cause depression?

The official regulatory label notes depression as an adverse reaction reported during post-marketing experience. This is classified as a less common event associated with the medicine.


Q: What happens when you stop taking Losap?

According to the official product information, when the medicine is stopped, the body’s levels of the hormones it influences, such as Angiotensin II, typically return to their original baseline values within about three days. Specific withdrawal symptoms are not explicitly detailed in the official regulatory documents.


Q: Do you get used to the initial side effects of Losap?

Patient information derived from regulatory sources states that initial side effects, such as dizziness or tiredness, frequently improve or go away as the body adjusts to the medication. If side effects persist or are severe, regulatory constraints advise seeking appropriate medical guidance.


Q: How is Losap eliminated from the body?

Losap (Losartan) and its active compound are eliminated from the body through dual pathways. Official pharmacokinetic data shows that the substance is cleared through both the urine (approximately 35% of the dose) and through feces/bile (approximately 60% of the dose).

How should Losap be stored and disposed of?

Storage and Disposal of Losartan Potassium Tablets

Losartan potassium tablets must be stored according to regulatory requirements to preserve product integrity.


Storage Conditions

Losartan tablets must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The medication must be kept in its original container, which should be tightly closed, and protected from light and moisture. Tablets must be stored out of the sight and reach of children.

If a pharmacist prepares a Losartan oral suspension, it requires refrigerated storage at 2 C to 8 C (36 F to 46 F) and is only stable for up to four weeks.


Official Disposal Procedures

Unused or expired Losartan product must not be disposed of via wastewater or household garbage. Disposal procedures must be handled according to local regulations. Patients are directed to consult a pharmacist for guidance on properly discarding the medicine.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Losap found in:

A-Z Index: